Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Therapeutically targeting pDCs in multiple myeloma

Dharminder Chauhan • 12 Sep 2019
IMW 2019
Multiple Myeloma Tagraxofusp

Dharminder Chauhan, JD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, explains how targeting bone marrow accessory cells in the tumor microenvironment, such as plasmacytoid dendritic cells (pDCs) which are in excess within multiple myeloma, could be used to increase responsiveness of the tumor cells to conventional and novel immune therapies. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Dharminder Chauhan

Proof-of-concept approach to overcome proteasome inhibitor resistance in myeloma 5:29
Proof-of-concept approach to overcome proteasome inhibitor resistance in myeloma
Dharminder Chauhan • 12 Sep 2019

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals